|
Dr. Geoffrey Allan brings over 20 years experience in drug research and development at both early-stage and mature companies to his role as Chief Executive Officer, President and Chairman of the Board of Insmed Incorporated.
Dr. Allan joined Insmed Pharmaceuticals in 1994 as President and Chief Technical Officer. Since that time, he has restructured the company, built a strong scientific, management and clinical organization, and raised more than $120 million in equity.
Prior to joining Insmed, Dr. Allan was Vice President of Drug Development at Whitby Research, Inc., where he was responsible for building and directing a development organization that managed a broad portfolio of drug development candidates.
From 1980 to 1987, Dr. Allan was Head of the Cardiovascular Research Section at the Wellcome Research Laboratories, where he led the development of the Cardiovascular Research Group, and ultimately created an extensive portfolio of drug discovery candidates.
Dr. Allan holds several patents and has been published extensively in cardiovascular research and therapeutic drug developments.
He received his Ph.D. in pharmacology from Cornell University Medical College. | 